IP Library › Granted Patent US 12,428,477
Granted Patent B2
US 12,428,477 · App. 17/434,315 · Granted Sep 30, 2025

Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same

Inventors: Paul A. Jaminet (Sudbury, MA); Shou-Ching S. Jaminet (Sudbury, MA); Edward H. Ha (Cambridge, MA); Leonard G. Presta (San Francisco, CA); Manish S. Hudlikar (Brookline, MA)
Assignee: ANGIEX, INC.
C07K16/28A61K47/68033A61K47/6849A61K2039/505C07K2317/21C07K2317/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,428,477
App. No.
17/434,315
Granted
Sep 30, 2025
Kind
B2
Abstract

Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, and antigen-binding fragments thereof. Methods of use of said ADCs are also described.

Claims (25)

1. An antibody-drug conjugate comprising (1) an anti-transmembrane 4 L six family member 1 (TM4SF1) antibody or an antigen binding fragment thereof conjugated to (2) a therapeutic molecule via a linker, wherein the anti-TMA4SF1 antibody or the antigen binding fragment thereof comprises a human IgG1 Fc region comprising (1) a cysteine residue at position N297, or (2) a cysteine residue at position N297 and one or more mutations selected from the group consisting of M252Y, S254T, and T256E; as numbered by the EU index as set forth in Kabat, wherein the linker comprises (1) acetamide and (2) a spacer of C6 alkylene, wherein the therapeutic molecule is conjugated to the cysteine at position 297, and wherein the anti-TM4SF1 antibody or the antigen binding fragment thereof comprises:

(a) a heavy chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 6, 7, and 8, respectively; and a light chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 12, 13, and 14, respectively;

(b) a heavy chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 18, 19, and 20, respectively; and a light chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 24, 25, and 26, respectively;

(c) a heavy chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 30, 31, and 32, respectively; and a light chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 36, 37, and 38, respectively;

(d) a heavy chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 42, 43, and 44, respectively; and a light chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 48, 49, and 50, respectively;

(e) a heavy chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 54, 55, and 56, respectively; and a light chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 60, 61, and 62, respectively;

(f) a heavy chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 66, 67, and 68, respectively; and a light chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 72, 73, and 74, respectively;

(g) a heavy chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 78, 79, and 80, respectively; and a light chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 84, 85, and 86, respectively;

(h) a heavy chain comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 94, 95, and 96, respectively; and a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NOs: 107 or 108, a CDR2 comprising the amino acid sequence of SEQ ID NO: 109, a CDR3 comprising the amino acid sequence of SEQ ID NOs: 110 or 111; or

(i) a heavy chain comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 115, a CDR2 domain comprising the amino acid sequence of SEQ ID NOs: 116 or 117, a CDR3 domain comprising the amino acid sequence of SEQ ID NOs: 118, 119, 120, or 121; and a light chain comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NOs: 124, 125, 126, or 127, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 128, a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 129.

2. The antibody-drug conjugate of claim 1 , wherein the anti-TM4SF1 antibody or the antigen binding fragment thereof comprises:

(A) the heavy chain in (a) comprising the amino acid sequence of SEQ ID NO: 3, and the light chain in (a) comprising the amino acid sequence of SEQ ID NO: 9;

(B) the heavy chain in (b) comprising the amino acid sequence of SEQ ID NO: 15, and the light chain in (b) comprising the amino acid sequence of SEQ ID NO: 21;

(C) the heavy chain in (c) comprising the amino acid sequence of SEQ ID NO: 27, and the light chain in (c) comprising the amino acid sequence of SEQ ID NO: 33;

(D) the heavy chain in (d) comprising the amino acid sequence of SEQ ID NO: 39, and the light chain in (d) comprising the amino acid sequence of SEQ ID NO: 45;

(E) the heavy chain in (e) comprising the amino acid sequence of SEQ ID NO: 51, and the light chain in (e) comprising the amino acid sequence of SEQ ID NO: 57;

(F) the heavy chain in (f) comprising the amino acid sequence of SEQ ID NO: 63, and the light chain in (f) comprising the amino acid sequence of SEQ ID NO: 69;

(G) the heavy chain in (g) comprising the amino acid sequence of SEQ ID NO: 75, and the light chain in (g) comprising the amino acid sequence of SEQ ID NO: 81;

(H) the heavy chain in (h) comprising the amino acid sequence of SEQ ID NO: 90, 92, 130, or 132, and the light chain in (h) comprising the amino acid sequence of SEQ ID NO: 97, 99, 101, 103, 105, 131, or 133; or

(I) the heavy chain in (i) comprising the amino acid sequence of SEQ ID NO: 1, 112, or 114, and the light chain in (i) comprising the amino acid sequence of SEQ ID NO: 2 or 122.

3. The antibody-drug conjugate of claim 1 or claim 2 , wherein the therapeutic molecule comprises a radioactive isotope, a cytotoxic agent, a chemotherapeutic agent, a prodrug activating enzyme, an anti-hormonal agent, or any combination thereof.

4. The antibody-drug conjugate of claim 1 or claim 2 , wherein the therapeutic molecule comprises at least one of a V-ATPase inhibitor, a pro-apoptotic agent, a B-cell lymphoma 2 (Bcl2) inhibitor, a myeloid cell leukemia 1 (MCL1) inhibitor, a HSP90 inhibitor, an inhibitor of apoptosis protein (IAP) inhibitor, an mTor inhibitor, a microtubule stabilizer, a microtubule destabilizer, an auristatin, a dolastatin, a maytansinoid, a MetAP (methionine aminopeptidase), an inhibitor of nuclear export of protein chromosome region maintenance 1 (CRM1), a dipeptidyl peptidase IV (DPPIV) inhibitor, a proteasome inhibitor, an inhibitor of phosphoryl transfer reactions in mitochondria, a protein synthesis inhibitor, a kinase inhibitor, a cyclin-dependent kinase 2 (CDK2) inhibitor, a cyclin-dependent kinase 9 (CDK9) inhibitor, a kinesin inhibitor, an histone deacetylase (HDAC) inhibitor, a DNA damaging agent, a DNA alkylating agent, a DNA intercalator, a DNA minor groove binder, a dihydrofolate reductase (DHFR) inhibitor, a CRISPR enzyme, or any combination thereof.

5. The antibody-drug conjugate of claim 1 or claim 2 , wherein the anti-TM4SF1 antibody or the antigen binding fragment thereof and the therapeutic molecule are conjugated by the linker in a single or a multistep protocol.

6. The antibody-drug conjugate of claim 1 or claim 2 , wherein the linker comprises a MC (6-maleimidocaproyl), a MCC (a maleimidomethyl cyclohexane-1-carboxylate), a MP (maleimidopropanoyl), a val-cit (valine-citrulline), a val-ala (valine-alanine), an ala-phe (alanine-phenylalanine), a PAB (p-aminobenzyloxycarbonyl), a SPP (N-Succinimidyl 4-(2-pyridylthio)pentanoate), 2,5-dioxopyrrolidin-1-yl 4-(pyridin-2-ylthio)hexanoate, 2,5-dioxopyrrolidin-1-yl 5-methyl-4-(pyridin-2-ylthio)hexanoate, 2,5-dioxopyrrolidin-1-yl 5-methyl-4-(pyridin-2-ylthio)heptanoate, 2,5-dioxopyrrolidin-1-yl 5-ethyl-4-(pyridin-2-ylthio)heptanoate, 2,5-dioxopyrrolidin-1-yl 4-cyclopropyl-4-(pyridin-2-ylthio)butanoate, 2,5-dioxopyrrolidin-1-yl 4-5-cyclobutyl-4-(pyridin-2-ylthio)butanoate, 2,5-dioxopyrrolidin-1-yl 4-cyclopentyl-4-(pyridin-2-ylthio)butanoate, 2,5-dioxopyrrolidin-1-yl 4-cyclohexyl-4-(pyridin-2-ylthio)butanoate, a SMCC (N-Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1 carboxylate), a SIAB (N-Succinimidyl (4-iodo-acetyl)aminobenzoate), or a spacer comprising an amide, an ester, an ether, substituted or unsubstituted C 1 -C 6 alkylene, substituted or unsubstituted C 1 -C 6 haloalkylene, substituted or unsubstituted C 1 -C 6 heteroalkylene, substituted or unsubstituted C 3 -C 8 cycloalkylene, substituted or unsubstituted C 2 -C 7 heterocycloalkylene, substituted or unsubstituted arylene, a substituted or unsubstituted heteroarylene, or any combination thereof.

7. The antibody-drug conjugate of claim 1 or claim 2 , wherein the linker is a cross-linking reagent that comprises iodoacetamide, bromoacetamide, vinyl pyridine, disulfide, pyridyl disulfide, isocyanate, isothiocyanate, N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), 2,5-dioxopyrrolidin-1-yl 3-cyclopropyl-3-(pyridin-2-yldisulfaneyl)propanoate, 2,5-dioxopyrrolidin-1-yl 3-cyclobutyl-3-(pyridin-2-yldisulfaneyl)propanoate, N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP), 2,5-dioxopyrrolidin-1-yl 4-cyclopropyl-4-(pyridin-2-yldisulfaneyl)butanoate, 2,5-dioxopyrrolidin-1-yl 4-cyclobutyl-4-(pyridin-2-yldisulfaneyl)butanoate, N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB), 2,5-dioxopyrrolidin-1-yl 4-cyclopropyl-4-(pyridin-2-yldisulfaneyl)butanoate, 2,5-dioxopyrrolidin-1-yl 4-cyclobutyl-4-(pyridin-2-yldisulfaneyl)butanoate, N-succinimidyl-4-(2-pyridyldithio)-2-sulfo-butanoate (sulfo-SPDB), N-succinimidyl iodoacetate (SIA), N-succinimidyl(4-iodoacetyl)aminobenzoate (SIAB), maleimide PEG NHS, N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (SMCC), N-sulfosuccinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (sulfo-SMCC), or 2,5-dioxopyrrolidin-1-yl 17-(2,5-dioxo-2, 5-dihydro-1 H-pyrrol-1-yl)-5,8,11,14-tetraoxo-4,7,10,13-tetraazaheptadecan-1-oate (CX1-1).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2021
From: JAMINET, PAUL A.; JAMINET, SHOU-CHING S.; HA, EDWARD H.; PRESTA, LEONARD G.
To: ANGIEX, INC.
Reel/Frame 057859/0255 →
Continuity (3)
Provisional Application 62811411 · Feb 27, 2019
Provisional Application 62967377 · Jan 29, 2020
Related Publication 20230096824A1 · Mar 30, 2023
References Cited (223)
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5571894A · Wels et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5587458A · King et al. · 1996 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6982321B2 · Winter · 2006 [cited by applicant]
US 7087409B2 · Barbas, III et al. · 2006 [cited by applicant]
US 7332581B2 · Presta · 2008 [cited by applicant]
US 7361740B2 · Hinton et al. · 2008 [cited by applicant]
US 7371826B2 · Presta · 2008 [cited by applicant]
US 7527791B2 · Adams et al. · 2009 [cited by applicant]
US 8088387B2 · Steeves et al. · 2012 [cited by applicant]
US 8163888B2 · Steeves et al. · 2012 [cited by applicant]
US 8198417B2 · Steeves et al. · 2012 [cited by applicant]
US 8969526B2 · Baehner et al. · 2015 [cited by applicant]
US 9803023B2 · Chamberlain et al. · 2017 [cited by applicant]
US 10155812B2 · Jaminet · 2018 [cited by examiner]
US 10745479B2 · Chun · 2020 [cited by examiner]
US 10844135B2 · Chari et al. · 2020 [cited by applicant]
US 11208495B2 · Jaminet · 2021 [cited by examiner]
US 20040214872A1 · Suto et al. · 2004 [cited by applicant]
US 20050014934A1 · Hinton et al. · 2005 [cited by applicant]
US 20050054832A1 · Lazar et al. · 2005 [cited by applicant]
US 20090136494A1 · Ponath et al. · 2009 [cited by applicant]
US 20120004117A1 · Aburatani et al. · 2012 [cited by applicant]
US 20120070379A1 · Black et al. · 2012 [cited by applicant]
US 20120213705A1 · Dimasi · 2012 [cited by examiner]
US 20140170140A1 · Bennett et al. · 2014 [cited by applicant]
US 20160102135A1 · Escobar-Cabrera · 2016 [cited by applicant]
US 20160229910A1 · Jaminet et al. · 2016 [cited by applicant]
US 20170216452A1 · Ma et al. · 2017 [cited by applicant]
US 20180043033A1 · Anderl · 2018 [cited by examiner]
US 20200268713A1 · Hutchinson et al. · 2020 [cited by applicant]
US 20210260209A1 · Jaminet et al. · 2021 [cited by applicant]
US 20220153860A1 · Jaminet et al. · 2022 [cited by applicant]
US 20220267461A1 · Jaminet et al. · 2022 [cited by applicant]
US 20230126271A1 · Jaminet et al. · 2023 [cited by applicant]
US 20230293713A1 · Jaminet et al. · 2023 [cited by applicant]
US 20230338572A1 · Jaminet et al. · 2023 [cited by applicant]
US 20230372518A1 · Jaminet et al. · 2023 [cited by applicant]
EP 0239400B1 · 1994 [cited by applicant]
EP 0592106B1 · 2004 [cited by applicant]
EP 0519596B1 · 2005 [cited by applicant]
EP 2235059B1 · 2015 [cited by applicant]
JP 2011501945A · 2011 [cited by applicant]
JP 2011507963A · 2011 [cited by applicant]
JP 2014533659A · 2014 [cited by applicant]
JP 2016520598A · 2016 [cited by applicant]
WO WO8807089A1 · 1988 [cited by applicant]
WO WO9109967A1 · 1991 [cited by applicant]
WO WO9209690A2 · 1992 [cited by applicant]
WO WO9316185A2 · 1993 [cited by applicant]
WO WO9429351A2 · 1994 [cited by applicant]
WO WO9951642A1 · 1999 [cited by applicant]
WO WO2004056312A2 · 2004 [cited by applicant]
WO WO2005100402A1 · 2005 [cited by applicant]
WO WO2006029879A2 · 2006 [cited by applicant]
WO WO2007059312A2 · 2007 [cited by applicant]
WO WO2007070659A2 · 2007 [cited by applicant]
WO WO2007079130A2 · 2007 [cited by applicant]
WO WO2007094916A2 · 2007 [cited by applicant]
WO WO2008077079A1 · 2008 [cited by applicant]
WO WO2008083346A1 · 2008 [cited by applicant]
WO WO2009086320A1 · 2009 [cited by applicant]
WO WO2009100309A3 · 2009 [cited by applicant]
WO WO2010037062A1 · 2010 [cited by applicant]
WO WO2011028195A2 · 2011 [cited by applicant]
WO WO2012166559A1 · 2012 [cited by applicant]
WO WO2012166560A1 · 2012 [cited by applicant]
WO WO2014190441A1 · 2014 [cited by applicant]
WO WO2015054427A1 · 2015 [cited by examiner]
WO WO2015184099A1 · 2015 [cited by applicant]
WO WO2019046338A1 · 2019 [cited by applicant]
WO WO2019241430A2 · 2019 [cited by applicant]
Rudikoff et al., PNAS 79: 1979-1983 (Year: 1982). [cited by examiner]
Wu et al., J. Mol. Biol. 294: 151-162 (Year: 1999). [cited by examiner]
Strop et al., Chemistry and Biology 20: 161-167 (Year: 2013). [cited by examiner]
Grevys et al., J Immunology 194: 5497-5508, (Year: 2015). [cited by examiner]
Piche-Nicholas et al., MABS 10(1): 81-94 (Year: 2018). [cited by examiner]
Extended European Search Report for EP Patent Application No. 20762413.1 dated Feb. 21, 2023. [cited by applicant]
Oganesyan et al.: Structural characterization of a human Fc fragment engineered for extended serum half-life. Molecular Immunology. 46(8-9): 1750-1755 (2009). [cited by applicant]
Rahim et al.: Three Members of Transmembrane-4-Superfamily, TM4SF1, TM4SF4, and TM4SF5, as Emerging Anticancer Molecular Targets against Cancer Phenotypes and Chemoresistance. Pharmaceuticals. 16(110):1-27 (2023). [cited by applicant]
U.S. Appl. No. 17/532,660 Final Office Action dated Nov. 30, 2023. [cited by applicant]
U.S. Appl. No. 17/532,660 Office Action dated Jun. 26, 2023. [cited by applicant]
U.S. Appl. No. 17/532,664 Office Action dated Aug. 18, 2023. [cited by applicant]
U.S. Appl. No. 17/532,664 Restriction Requirement dated May 15, 2023. [cited by applicant]
U.S. Appl. No. 17/532,665 Final Office Action dated Jan. 22, 2024. [cited by applicant]
Yu et al.: Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrobial Agents and Ch… [cited by applicant]
Agard NJ, Bertozzi CR. Chemical approaches to perturb, profile, and perceive glycans. Acc Chem Res. Jun. 16, 2009;42(6):788-97. [cited by applicant]
Almagro et al. Humanization of antibodies. Front Biosci 13:1619-1633 (2008). [cited by applicant]
Altschul et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25(17) 3389-3402 (1997). [cited by applicant]
An Z. et al. IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs. Nov.-Dec. 2009; 1(6):572-9. [cited by applicant]
Angal, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody.Mol Immunol. Jan. 1993;30(1):105-108. [cited by applicant]
Baca et al. Antibody humanization using monovalent phage display. J Biol Chem 272(16):10678-10684 (1997). [cited by applicant]
Bass, et al. Hormone phage: an enrichment method for variant proteins with altered binding properties. Proteins. 1990;8(4):309-314. [cited by applicant]
Boeggeman E. et al. Direct identification of nonreducing GlcNAc residues on N-glycans of glycoproteins using a novel chemoenzymatic method. Bioconjug Chem. May-Jun. 2007;18(3):806-14. [cited by applicant]
Brennan et al. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin fragments. Science 229:81-83 (1985). [cited by applicant]
Brodeur, et al. In: Monoclonal Antibody Production Techniques and Applications. New York: Marcel Dekker; 1987:51-63. [cited by applicant]
Brown et al. Tolerance of single, but not multiple, amino acid replacements in antibody Vh Cdr 2: a means of minimizing B cell wastage from somatic hypermutation? J Immunol 156(9):3285-3291 (1996). [cited by applicant]
Bruggemann, M., et al., Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies, J. Exp. Med. 166 (1987) 1351-1361). [cited by applicant]
Campbell CT. et al. Metabolic oligosaccharide engineering: perspectives, applications, and future directions. Mol Biosyst. Mar. 2007;3(3):187-94. [cited by applicant]
Canfield, et al. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. Exp Med. Jun. 1, 1991;173(6):1483-91. [cited by applicant]
Carter et al., Bio/Technology 10: 163-167 (1992). [cited by applicant]
Carter et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Pnas USA 89(10):4285-4289 (1992). [cited by applicant]
Chang et al., CD13 (Aminopeptidase N) Can Associate With Tumor-Associated Antigen L6 and Enhance the Motility of Human Lung Cancer Cells, Int J Cancer. 1 16: 243-252, 2005. [cited by applicant]
Chappel et al. Identification of the Fey receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies, PNAS, Oct. 1991, 88:9036-9040. [cited by applicant]
Chaudhary, V.K., et al., A Rapid Method of Cloning Functional Variable-Region Antibody Genes in [cited by applicant]
Chen, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. Nov. 5, 1999;293(4):865-81. [cited by applicant]
Chothia et al. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196:901-917 (1987). [cited by applicant]
Chothia, et al. Conformations of immunoglobulin hypervariable regions. Nature 342(6252):877-83 (1989). [cited by applicant]
“Sciuto et al., Intracellular distribution of TM4SF1 and internalization of TM4SF1-antibody complex in vascular endothelial cells Biochem Biophys Res Commun, vol. 465, pp. 338-343 (2015).” [cited by applicant]
Clark, et al. Direct in-gel fluorescence detection and cellular imaging of O-GlcNAc-modified proteins. J Am Chem Soc. Sep. 3, 2008;130(35):11576-11577. doi: 10.1021/ja8030467. Epub Aug. 7, 2008. [cited by applicant]
Clynes, et al. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A. Jan. 20, 1998;95(2):652-6. [cited by applicant]
Cragg, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. Feb. 1, 2003;101(3):1045-1052. [cited by applicant]
Cragg, M. S, and M. J. Glennie, Antibody specificity controls in vivo effector mechanisms of aniti-CD20 reagents, Blood 103:2738-2743 (2004). [cited by applicant]
Dall'Acqua WF. et al. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. Aug. 18, 2006;281(33):23514-24. [cited by applicant]
Dall'Acqua, et al. Antibody humanization by framework shuffling. Methods. May 2005;36(1):43-60. [cited by applicant]
Duncan and Winter, The binding site for Clq and IgG. Nature, 322:738-40, 1988. [cited by applicant]
Edwards, C P et al., “Cloning of the Murine Counterpart of the Tumor-Associated Antigen H-L6: Epitope Mapping of the Human and Murine L6 Antigens”, Biochemistry, vol. 34, Jan. 1, 1995, pp. 12653-12660. [cited by applicant]
“Extended European search Report for corresponding EP Application No. 18849908.1 issued Apr. 28, 2021”. [cited by applicant]
“Fell, H P et al., “Chimeric L6 antitumore antibody”, Journal of Biological Chemistry, american Society for Biochesmistry and Molecular Biology, vo. 267, No. 22, Aug. 5, 1992, pp. 15552-15558”. [cited by applicant]
Gazzano-Santoro et al. A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J Immunol Methods 202(2):163-171 (Mar. 28, 1997). [cited by applicant]
Geuijen et al. Affinity ranking of antibodies using flow cytometry: application in antibody phage display-based target discovery. Journal of Immunological Methods 302(1): 68-77 (2005). [cited by applicant]
Goding J. Production of monoclonal antibodies. In: Monoclonal Antibodies: Principles and Practice. London; New York: Academic Press; 1986:59-103. [cited by applicant]
Griffiths et al. Human anti-self antibodies with high specificity from phage display libraries. Embo J. 12(2):725-734 (1993). [cited by applicant]
Grimm HP. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharmacokinet Pharmacodyn. Oct. 2009;36(5):407-20. [cited by applicant]
Grisham R. et al. Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management. Gynecol Oncol Res Pract. Jan. 5, 2018;5:1. [cited by applicant]
Guex and Peitsch, Swiss-Model and the Swiss-PdbViewer: An environment for comparative protein modeling, 1997, Electrophoresis 18:2714-23. [cited by applicant]
Guyer, et al. Immunoglobulin binding by mouse intestinal epithelial cell receptors. J Immunol. Aug. 1976;117(2):587-593. [cited by applicant]
Hamblett KJ. et al. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability. Mol Pharm. Jul. 5, 2016;13(7):2387-96. [cited by applicant]
“Hellstrom, I et al., “Antitumor effects of L6, and IgG2a antibody that reacts with most human carcinomas”, Proceedings of the National Academy of Sciences, National Academy of Sciences, US, Vo. 83, No. 18, Sep. 1, 1986… [cited by applicant]
Hellstrom, I, et al. “Monoclonal Mouse Antibodies Raised Against Human Lung Carcinoma”, Cancer Research, Vo. 46, No. 8, Aug. 1, 1986, pp. 3917-3923. [cited by applicant]
Hellstrom, I., et al., Strong antitumor activities of IgG3 antibodies to a human melanoma- associated ganglioside, Proc. Nat'l Acad. Sci. USA 82 (1985) 1499-1502. [cited by applicant]
Hezareh M. et al. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol. Dec. 2001;75(24):12161-8. [cited by applicant]
Hinton, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem. Feb. 20, 2004;279(8):6213-6. Epub Dec. 29, 2003. [cited by applicant]
Hinton PR. et al. An engineered human IgG1 antibody with longer serum half-life. J Immunol. Jan. 1, 2006;176(1):346-56. [cited by applicant]
Honegger et al.: Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. J Mol Biol 309(3):657-70 (2001). [cited by applicant]
Hoogenboom, et al. By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J Mol Biol. Sep. 20, 1992;227(2):381-8. [cited by applicant]
Idusogie, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. Apr. 15, 2000;164(8):4178-84. [cited by applicant]
Idusogie, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human lgG1 Fc. J Immunol. Apr. 1, 20005;164(8):4178-84. [cited by applicant]
Jones, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. May 29-Jun 4, 1986;321(6069):522-5. [cited by applicant]
Karlin, S. et al., “Applications and statistics for multiple high-scoring segments in molecular sequences”, PNAS, 1993, vol. 90, pp. 5873-5877. [cited by applicant]
Kashmiri et al., SDR grafting—a new approach to antibody humanization, Methods vol. 36, No. 1, pp. 25-34, May 2005. [cited by applicant]
Khanna and Hunter, Modeling Metastais In Vivo, Carcinogenesis, Mar. 205:26(3):513-23. [cited by applicant]
Khidekel, et al. A Chemoenzymatic Approach toward the Rapid and Sensitive Detection of O-GlcNAc Posttranslational Modifications. J. Am. Chem. Soc. 2003; 125(52):16162-16163. [cited by applicant]
Kida S. et al., Studies on heterobifunctional cross-linking reagents, 6-maleimidohexanoic acid active esters. Chem Pharm Bull (Tokyo). Apr. 2007;55(4):685-7. [cited by applicant]
Klimka et al., Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning, Br. J. Cancer, 83:252-260 (2000). [cited by applicant]
Kohler and Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature, Aug. 7, 1975;256(5517):495-7. [cited by applicant]
Kozbor, A human hybrid myeloma for production of human monoclonal antibodies, 1984, Immunol. 133:3001-05. [cited by applicant]
Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. Feb. 2017; 16(2):101-114. doi: 10.1038/nrd.2016.211. Epub Nov. 25, 2016. [cited by applicant]
Le Gall et al. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody. J Immunol Methods 285(1):111-127 (2004). [cited by applicant]
Levengood MR et al. Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates. Angew Chem Int Ed Engl. Jan. 16, 2017;56(3):733-737. [cited by applicant]
Li X. et al. Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. Angew Chem Int Ed Engl. Jul. 7, 2014;53(28):7179-82. [cited by applicant]
“Lin et al. TM4SF1: a new vascular therapeutic target in cancer, Angiogenesis vol. 17, pp. 897-907 (2014)”. [cited by applicant]
“Liu, A Y et al., ”Chimeric Mouse-Human IGG1 Antibody That can Mediate Lysis of Cancer Cells“ Proceedings of the National Academy of Sciences, National Academy of Sciences, US, vol. 84, May 1, 1987, pp. 3439-3443”. [cited by applicant]
Liu et al. Adding new chemistries to the genetic code. Annu Rev Biochem 79:413-444 (2010). [cited by applicant]
Lowenthal MS et al. Identification of Novel N-Glycosylation Sites at Noncanonical Protein Consensus Motifs. J Proteome Res. Jul. 1, 2016;15(7):2087-101. [cited by applicant]
Maccallum et al.: Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol. 262(5):732-745 (1996). [cited by applicant]
“Markens, John S, et al., “Membrane Topology of the L6 Antigen an dldentification of the Protein Epitope Recognized by the L6 Monoclonal Antibody” INC the Journal of Biological Chemistry, vo. 269, No. 10, Mar. 11, 1994,… [cited by applicant]
Marks et al. By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (NY) 10(7):779-783 (1992). [cited by applicant]
Morimoto K, Inouye K. Single-step purification of F(ab')2 fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW. J Bioche… [cited by applicant]
Morrison et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. PNAS USA 81(21):6851-6855 (1984). [cited by applicant]
Munson et al. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 107(1):220-239 (Sep. 1, 1980). [cited by applicant]
O'Shannessy DJ et al. A novel procedure for labeling immunoglobulins by conjugation to oligosaccharide moieties. Immunol Lett. 1984;8(5):273-7. [cited by applicant]
Osbourn, et al. From rodent reagents to human therapeutics using antibody guided selection. Methods. May 2005;36(1):61-68. [cited by applicant]
Padlan, et al., A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol 28(4-5):489-498 (1991). [cited by applicant]
Padlan, et al. Identification of specificity-determining residues in antibodies. FASEB J. 1995; 9(1):133-9. [cited by applicant]
PCT/US2020/020207 International Preliminary Report on Patentability dated Aug. 25, 2021. [cited by applicant]
PCT/US2020/020207 International Search Report and Written Opinion dated Aug. 10, 2020. [cited by applicant]
Pearson, W.R. Using the FASTA Program to Search Protein and DNA Sequence Databases. Meth. Mol. Biol. 1994; 24:307-331. [cited by applicant]
Petkova, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. Dec. 2006;18(12):1759-1769. [cited by applicant]
Pluckthun, A. Mono- and bivalent antibody fragments produced in [cited by applicant]
Presta et al. Humanization of an antibody directed against IgE. J Immunol 151:2623-2632 (1993). [cited by applicant]
Queen C., et al., “A humanized antibody that binds to the interleukin 2 receptor,” Dec. 1989, Proceedings of the National Academy of Sciences, National Academy of Sciences, vol. 86, No. 24, pp. 10029-10033, XP002614478. [cited by applicant]
Rabuka, David et al. Site-Specific chemical protein conjugation using genetically encoded aldehyde tags. Nat. Protoc. 7(6):1052-1067 (2012). [cited by applicant]
Richman et al. Radioimmunotherapy for breast cancer using escalating fractionated doses of 1311-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 55(23 Suppl):5916s-5920s (Dec. … [cited by applicant]
Riechmann et al. Reshaping human antibodies for therapy. Nature, 332.6162:323-7 (1988). [cited by applicant]
Roberts et al. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54: 459-476 (2002). [cited by applicant]
Roguska et al. Humanization of murine monoclonal antibodies through variable domain resurfacing. PNAS 91:969-973 (1994). [cited by applicant]
Rosok et al. A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab. J Biol Chem 271:22611-22618 (1996). [cited by applicant]
Rychly, et al., Therapeutic Strategies in Autoimmune Diseases by Interfering With Leukocyte Endothelium Interaction Curr Pharm Des. 2006;12(29):3799-806. [cited by applicant]
Sali, Andrej and Blundell, T., Comparative Protein Modelling by Satisfaction of Spatial Restraints, 1993, J. Mol. Biol. 234:779-815). [cited by applicant]
Saxena and Christofori, Rebuilding cancer metastasis in the mouse, Mol Oncol. Apr. 2013;7(2):283-96. [cited by applicant]
Saxena et al., Advances in Therapeutic Fc Engineering—Modulation of IgG-Associated Effector Functions and Serum Half-life, Front Immunol. Dec. 1, 20162;7:580, | https://doi.org/10.3389/fimmu.2016.00580. [cited by applicant]
Shields et al. High Resolution Mapping of the Binding Site on Human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcyR. J Biol Chem 276(9):6591-6604 (2001). [cited by applicant]
Shih, et al., The L6 Protein TM4SF1 is Critical for Endothelial Cell Function and Tumor Angiogenesis, Available in PMC Apr. 15, 2010, published in final edited form as: Cancer Res. 69(8):3272-3277 (2009) (12 pages). [cited by applicant]
Silva et al., The S228P Mutation Prevents in Vivo and in Vitro IgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation (J Biol Chem. Feb. 27, 201… [cited by applicant]
Sims et al., 1993, A humanized CD18 antibody can block function without cell destruction., J. Immunol. 151:2296-308. [cited by applicant]
Skerra, A. Bacterial expression of immunoglobulin fragments. Curr Opin Immunol. Apr. 1993;5(2):256-262. [cited by applicant]
Sondermann, et al. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature. Jul. 20, 2000;406(6793):267-73. [cited by applicant]
Strop P. Versatility of microbial transglutaminase. Bioconjug Chem. May 21, 2014;25(5):855-62. [cited by applicant]
Studnicka et al.: Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Eng. 7(6):805-814 (1994). [cited by applicant]
“Stenzel-Johnson, P R, et al., “Identification of Residues in the Monoclonal Antitumore Antibody L6 Important for Binding to its Tumor Antigen”, Biochemistry, Vo. 33, Jan. 1, 1994, pp. 14400-14406”. [cited by applicant]
Vajdos et al. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol. 320(2):415-28 (2002). [cited by applicant]
Valliere-Douglass JF et al. Asparagine-linked oligosaccharides present on a non- consensus amino acid sequence in the CH1 domain of human antibodies. J Biol Chem. Nov. 20, 2009;284(47):32493-506. [cited by applicant]
Verhoeyen et al. Reshaping human antibodies: Grafting an antilysozyme activity. Science 239:1534-1536 (1988). [cited by applicant]
Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. Oct. 20, 2014;5:520. doi: 10.3389/fimmu.2014.00520. [cited by applicant]
“Visintin et al., Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature Mol Cancer Ther, vol. 14, No. 8, pp. 1868-1876 (2015).” [cited by applicant]
Wang et al. Expanding the genetic code. Angew Chem Int Ed, 2005, , pp. 34-66, vol. 44, No. 1, e-pub Dec. 17, 2004. [cited by applicant]
Watt GM, et al., Site-specific glycosylation of an aglycosylated human IgG1-Fc antibody protein generates neoglycoproteins with enhanced function. Chem Biol. Sep. 2003;10(9):807-14. doi: 10.1016/j.chembiol.2003.08.006. [cited by applicant]
Whitelegg et al. : WAM: an improved algorithm for modelling antibodies on the WEB. Protein Eng. 13:819-24 (2000). [cited by applicant]
Winter et al., Making Antibodies by Phage Display Technology, 1994, Ann. Rev. Immunol. 12:433-55. [cited by applicant]
Wright, et al., The L6 membrane proteins—A new four-transmembrane superfamily, Protein Sci. 9: 1594-1600, 2000. [cited by applicant]
Yang NJ et al. Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins. Nucleic Acids Res. Jul. 27, 2017;45(13):7602-7614. [cited by applicant]
Zhou Q. et al. Site-specific antibody-drug conjugation through glycoengineering. Bioconjug Chem. Mar. 19, 2014;25(3):510-20. [cited by applicant]
Zuberbühler K. et al. Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format. Chem Commun (Camb). Jul. 18, 2012;48(56):7100-2. [cited by applicant]
Zukauskas et al., TM4SF1: A tetraspanin-like protein necessary for nanopodia formation and endothelial cell migration, Available in PMC Mar. 11, 2012, published in final edited form as: Angiogenesis. 14(3):345-354 (2011… [cited by applicant]
Japanese Application No. 2021-550149 Office Action dated Jan. 31, 2024. [cited by applicant]
U.S. Appl. No. 17/532,660 Office Action dated Apr. 30, 2024. [cited by applicant]
Gao, Caiyun et al. TM4SF1 is a Potential Target for Anti-invasion and Metastasis in Ovarian Cancer. BMC Cancer 19(1)237, 1-12 (2019). [cited by applicant]
U.S. Appl. No. 17/532,664 Office Action dated Jul. 19, 2024. [cited by applicant]